Clinical trial

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01315249

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-03-01

PhasePHASE3

Study timeline

Study start (unknown)2011-03-01Date precision: month

Registry last updated2013-08-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Obstructive Pulmonary Disease (COPD)unresolved

Interventions

indacaterol and glycopyrronium (QVA149)DRUG

Placebo to fluticasone/salmeterolDRUG

fluticasone/salmeterolDRUG

Placebo to indacaterol and glycopyrronium (QVA149)DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

BerlinGermany6 SeoulSouth Korea4 HamburgGermany3 BudapestHungary1 BrusselsBelgium1 MünchenGermany1 HanoverGermany1 FrankfurtGermany1 DaeguSouth Korea1 UlmGermany1 BonnGermany1 LübeckGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01315249 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.